お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
974750

LUM001-新たな洞察と市場予測:2030年

LUM001- Emerging Insight and Market Forecast - 2030

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 60 Pages | 納期: 約10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=107.78円
LUM001-新たな洞察と市場予測:2030年
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 60 Pages
納期: 約10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

LUM001は、腸の胆汁酸を循環に戻す頂端側ナトリウム依存性胆汁酸輸送体(ASBT)の阻害剤です。 LUM001は、1日1回の経口錠剤で血清胆汁酸を減らすことにより、多くの胆汁うっ滞性肝疾患に関連する重度のかゆみや進行性肝障害を軽減するための新しい治療法を提供する可能性があります。 LUM001は、原発性胆汁性肝硬変、進行性家族性肝内胆汁うっ滞、アラジール症候群、原発性硬化性胆管炎を含む4つの希少な胆汁うっ滞性肝疾患において、米国食品医薬品局(FDA)からオーファンドラッグ指定を受けています。

世界中での広範な研究と増加するヘルスケア費のため、今後数年間で、アラジール症候群の市場シナリオは変化するとみられています。これにより、市場の規模が拡大し、製薬会社がより多くの市場に参入できるようになります。

企業や学術関係者は、課題の評価とともに、LUM001の優位性に影響を与える可能性のある機会を模索しています。開発中の治療法は、病状を治療/改善するための新しいアプローチに焦点を合わせています。

アラジール症候群のためのその他の新製品はLUM001と市場で競合しており、近い将来、新興の治療法が上市されることで市場に大きな影響を与えるでしょう。

規制のマイルストーン、開発活動、およびいくつかの重要な研究結果は、LUM001の現在の開発シナリオを提供します。

2020年から2030年までのLUM001の予測売上データを詳細に分析することで、LUM001の全体的なシナリオを特定し、治療ポートフォリオに関する意思決定プロセスにおいてクライアントをサポートします。

当レポートは、7つの主要市場におけるアラジール症候群の治験薬について包括的に扱います。2020年から2030年までの調査期間における、米国、欧州5ヶ国(ドイツ、フランス、イタリア、スペイン、英国)、および日本の7つの主要市場におけるLUM001の詳細な概要を製品の詳細とともに提供します。製品の詳細には、作用機序、投与量と管理、合成経路、規制のマイルストーンを含む研究開発活動、およびその他の開発活動が含まれます。さらに、市場予測、 SWOT分析、市場における競合動向、およびその他の新たな治療法など将来の市場動向を提供しています。

目次

第1章 薬剤概要

  • 製品の詳細
  • 作用機序
  • 投与量と管理
  • 研究開発活動
    • 臨床開発
    • 安全性と有効性
  • その他の開発活動

第2章 市場評価

  • 主要7ヶ国市場分析
  • 米国市場
  • ドイツ市場
  • フランス市場
  • イタリア市場
  • スペイン市場
  • 英国市場
  • 日本市場

第3章 SWOT分析

第4章 アナリストの見解

第5章 市場の競合動向

第6章 その他の新しい治療法

第7章 付録

第8章 レポート購入オプション

図表

List of Tables

  • Table 1 LUM001, Description
  • Table 2 LUM001, Clinical Trial Description
  • Table 3 LUM001, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of LUM001
  • Figure 2 Patent Details, LUM001
  • Figure 3 LUM001, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 LUM001, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 LUM001, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 LUM001, Japan Market Size from 2020 to 2030 (in Millions USD)
目次
Product Code: DIDM0131

"LUM001- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Alagille syndrome in 7 Major Markets. A detailed picture of the LUM001 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview:

LUM001 is an inhibitor of the apical sodium-dependent bile acid transporter (ASBT), which recycles intestinal bile acids back into the circulation. By reducing serum bile acids with a once-daily oral tablet, LUM001 may offer a novel therapeutic approach for alleviating the severe itching and progressive liver damage associated with many cholestatic liver diseases. LUM001 has received Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) Office of Orphan Product Development in four rare cholestatic liver diseases including primary biliary cirrhosis; progressive familial intrahepatic cholestasis; Alagille syndrome; and primary sclerosing cholangitis.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around LUM001.
  • The report contains forecasted sales for LUM001 till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase II) for Alagille syndrome.
  • The report also features the SWOT analysis with analyst insights and key findings of LUM001.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

LUM001 Analytical Perspective by DelveInsight

  • In-depth LUM001 Market Assessment

This report provides a detailed market assessment of LUM001 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • LUM001 Clinical Assessment

The report provides the clinical trials information of LUM001 covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Alagille syndrome is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence LUM001 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Alagille syndrome are giving market competition to LUM001 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of LUM001.
  • Our in-depth analysis of the forecasted sales data of LUM001 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the LUM001.

Key Questions:

  • Which company is developing LUM001 along with the phase of the clinical study?
  • What is the technology utilized in the development of LUM001?
  • What is the product type, route of administration and mechanism of action of LUM001?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the LUM001 development?
  • What are the key designations that have been granted to LUM001?
  • What is the forecasted market scenario of LUM001?
  • What is the history of LUM001 and what is its future?
  • What is the forecasted sales of LUM001 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to LUM001?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.